Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback